Abstract

Utilizing Private-Public Partnerships for Development and Implementation of Microphysiological Systems

Kristin Fabre, Microphysiological Systems Lead, Drug Safety & Metabolism, AstraZeneca

Tissue Chips (or Microphysiological Systems; MPS) are bioengineered tools being developed for predicting efficacy and toxicity of candidate compounds.  MPS development has progressed to a point where engagement of pharmaceutical and biotech industries will significantly help the continued development and implementation of these technologies.  This session will address the potential for commercializing tissue chip technology, and how industry can partner with public funding bodies to advance the field of this technology.